Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics


Adial Pharmaceuticals, Inc (ADIL)

Today's Latest Price: $1.95 USD

0.06 (3.17%)

Updated Nov 27 1:00pm

Add ADIL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ADIL Stock Price Chart Interactive Chart >

Price chart for ADIL

ADIL Price/Volume Stats

Current price $1.95 52-week high $4.00
Prev. close $1.89 52-week low $1.00
Day low $1.90 Volume 266,632
Day high $1.96 Avg. volume 1,031,046
50-day MA $1.82 Dividend yield N/A
200-day MA $1.54 Market Cap 27.73M

Adial Pharmaceuticals, Inc (ADIL) Company Bio


Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.


ADIL Latest News Stream


Event/Time News Detail
Loading, please wait...

ADIL Latest Social Stream


Loading social stream, please wait...

View Full ADIL Social Stream

Latest ADIL News From Around the Web

Below are the latest news stories about Adial Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADIL as an investment opportunity.

Adial Pharmaceuticals receives COVID-19 antibody rapid test devices order

Adial Pharmaceuticals ([[ADIL]] -28.1%) received an initial firm order for the purchase of 10K Assure/FaStep COVID-19 IgG/IgM Rapid Test Devices from a California-based technology corporation.The FaStep COVID-19 IgG/IgM Rapid Test Device is the first serology point-of-care test for COVID-19 using fingerstick blood samples approved by the U.S. FDA.The FaStep COVID-19 IgG/IgM Rapid Test...

Seeking Alpha | September 30, 2020

Adial Pharmaceuticals, Spero Therapeutics leads healthcare gainers, Myovant Sciences, TransMedics Group among major losers

Gainers: Adial Pharmaceuticals (ADIL) +33%, Spero Therapeutics (SPRO) +16%, LogicBio Therapeutics (LOGC) +14%, AngioDynamics (ANGO) +14%, Windtree Therapeutics (WINT) +10%.Losers: Myovant Sciences (MYOV) -21%, TransMedics Group (TMDX) -12%, COMPASS Pathways (CMPS) -9%, Beam Therapeutics (BEAM) -8%, American Shared Hospital Services (AMS) -5%....

Seeking Alpha | September 29, 2020

Why Adial Pharmaceuticals Is Trading Higher Today

Adial Pharmaceuticals (NASDAQ: ADIL ) shares are trading higher on Tuesday after the company announced the FDA has issued an emergency use authorization for the company's Assure/FaStep COVID-19 IgG/IgM rapid … Full story available on Benzinga.com

Benzinga | September 29, 2020

Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder

EMA Agreement paves the way for a marketing authorization in Europe after Phase 3CHARLOTTESVILLE, VA / ACCESSWIRE / July 22, 2020 / Adial Pharmaceuticals, Inc.

Yahoo | July 22, 2020

Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia

CHARLOTTESVILLE, VA / ACCESSWIRE / July 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL:ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approvals in Sweden and Estonia to commence the Company's landmark ONWARD™ pivotal Phase 3 clinical trial to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. The Swedish Medical Products Agency and Swedish Ethical Review Authority have provided approval for ONWARD™ to commence in Sweden; and the Estonian State Agency of Medicines and Ethics Review Committee overseeing human trials gran...

Yahoo | July 6, 2020

Read More 'ADIL' Stories Here

ADIL Price Returns

1-mo 12.72%
3-mo 44.44%
6-mo 20.74%
1-year 36.35%
3-year N/A
5-year N/A
YTD -19.09%
2019 -52.93%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9116 seconds.